The first generic version of Motegrity has been approved by the Food and Drug Administration and is now available.

NeurAxis's robust sales growth and disciplined cost management have set the stage for achieving cash flow breakeven in 2026. Notably, recent investments from life science-focused funds have bolstered ...

NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...

Pelvic floor dysfunction results in miscoordination between pelvic muscles, organs, and the brain. Find treatment for a tight ...

C, you may be concerned about what you can safely eat. This article includes tips on which foods to eat and avoid to help you ...

The talks on drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that ...

VIVUS will be discussing its significant 2024 momentum during the J.P. Morgan Healthcare Conference, with an emphasis on what we as a company aim to achieve during the coming months around our novel ...

Medicare is set to negotiate with manufacturers on 15 drugs in an effort to lower their prices for consumers nationwide. The Biden Administration announced that the Inflation Reduction Act cut the ...

A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without ...

Diseases of the joints are known as arthritis. The term is derived from the Greek word that means exactly that: diseases of ...

With the holidays past and the new year arrived, we look ahead — to losing weight. For some that resolve theoretically ...

Exercise: Regular exercise can help maintain a healthy body and weight, which lowers the risk of colon cancer. Aim for 150 ...